Product
HPN217
1 clinical trial
3 indications
Indication
Multiple Myeloma in RelapseIndication
Multiple MyelomaIndication
Multiple Myeloma With Failed RemissionClinical trial
A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2024-01-02